Picture of MapLight Therapeutics logo

MPLT MapLight Therapeutics Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMid CapNeutral

Annual cashflow statement for MapLight Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2022
December 31st
2023
December 31st
2024
December 31st
Period Length:12 M12 M12 M
Source:PROSPECTUSPROSPECTUSPROSPECTUS
Standards:
USG
USG
USG
Status:FinalFinalFinal
Net Income/Starting Line-30-55.7-77.6
Depreciation
Non-Cash Items3.3-1.42-0.483
Unusual Items
Other Non-Cash Items
Changes in Working Capital-0.4314.56-1.45
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Other Operating Cash Flow
Cash from Operating Activities-26.6-52-78.8
Capital Expenditures-0.746-0.462-0.77
Purchase of Fixed Assets
Other Investing Cash Flow Items-80
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities-0.746-0.462-80.8
Financing Cash Flow Items-2.19
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Cash from Financing Activities33.2105118
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash5.8552.1-41.5